EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ADAR1 Promotes the Progression and Temozolomide Resistance of Glioma Through p62‐Mediated Selective Autophagy

Yuyan Zhang, Huiling Guo, Jiahao Bu, Weiwei Wang iD, Li Wang, Zhibo Liu, Yuning Qiu, Qimeng Wang, Lijuan Zhou, Xianzhi Liu, Liwei Ma, Jianwei Wei iD

CNS Neuroscience & Therapeutics · 2025

DOI: 10.1111/cns.70168 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2025. Verfasst von Yuyan Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Temozolomide, Drug Resistance, Neoplasm, Autophagy, RNA-Binding Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation for Innovative Research Groups of the National Natural Science Foundation of China, Medical Science and Technology Project of Henan Province, Henan Province Outstanding Young Talent Project in Health Science and Technology Innovation for Young and Middle-aged People.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Resistance to temozolomide (TMZ) remains is an important cause of treatment failure in patients with glioblastoma multiforme (GBM). ADAR1, as a member of the ADAR family, plays an important role in cancer progression and chemotherapy resistance. However, the mechanism by which ADAR1 regulates GBM progression and TMZ resistance is still unclear.

Methods

We first constructed stable transfected strains in which ADAR1 was knocked down and overexpressed to investigate the effect of ADAR1 on the first‐line glioma chemotherapy drug TMZ. Subsequently, we validated that ADAR1 induces autophagy activation and used autophagy inhibitors to suppress autophagy, demonstrating that ADAR1 enhances TMZ resistance through autophagy. We further knocked down p62 (SQSTM1) based on the overexpression of ADAR1, and the results showed that ADAR1 regulates selective autophagy through the p62 regulation. Finally, we demonstrated through mutations at both edited and nonedited sites that ADAR1 regulates selective autophagy in an edited dependent way.

Results

Further analysis showed that in the presence of TMZ, elevated ADAR1 promoted TMZ induced autophagy activation. Further research revealed that ADAR1 enhances TMZ resistance through p62‐mediated selective autophagy. Further, ADAR1 regulates selective autophagy in an edited dependent way. Our results indicate a relationship between ADAR1 levels and the response of glioma patients to TMZ treatment.

Conclusions

We found that the expression of ADAR1 is upregulated in GBM and is associated with tumor grade and TMZ resistance. Elevated expression of ADAR1 predicts poor prognosis in GBM patients and promotes tumor growth in vivo or in vitro.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideDrug Resistance, NeoplasmAutophagyRNA-Binding ProteinsAntineoplastic Agents, AlkylatingSequestosome-1 ProteinAdenosine DeaminaseGliomaBrain NeoplasmsHumansCell Line, TumorDisease ProgressionAnimalsGlioblastoma

Stichwörter der Autor:innen

ADAR1TMZ resistanceautophagygliomap62

Substanzen

TemozolomideRNA-Binding ProteinsADAR protein, humanAntineoplastic Agents, AlkylatingSequestosome-1 ProteinAdenosine DeaminaseSQSTM1 protein, humanP62 protein, human

Autor:innen und Institutionen

  • Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Key Clinical Laboratory of Henan Province, Zhengzhou, Henan, China.
  • Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Electron Microscopy Laboratory of Renal Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

ORCID-Profile: Weiwei Wang, Jianwei Wei

Förderung

  • Foundation for Innovative Research Groups of the National Natural Science Foundation of China
  • Medical Science and Technology Project of Henan Province
  • Henan Province Outstanding Young Talent Project in Health Science and Technology Innovation for Young and Middle-aged People
  • Henan Province Key Research and Development (R & D) program
  • Key scientific research project plan of colleges and universities in Henan Province
  • Key project of Henan Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, Y., Guo, H., Bu, J., Wang, W., Wang, L., Liu, Z., Qiu, Y., Wang, Q., Zhou, L., Liu, X., Ma, L., & Wei, J. (2025). ADAR1 Promotes the Progression and Temozolomide Resistance of Glioma Through p62‐Mediated Selective Autophagy. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70168

Vancouver

Zhang Y, Guo H, Bu J, Wang W, Wang L, Liu Z, et al. ADAR1 Promotes the Progression and Temozolomide Resistance of Glioma Through p62‐Mediated Selective Autophagy. CNS Neuroscience & Therapeutics. 2025. doi:10.1111/cns.70168

BibTeX
@article{Zhang2025,
  author = {Zhang, Yuyan and Guo, Huiling and Bu, Jiahao and Wang, Weiwei and Wang, Li and Liu, Zhibo and Qiu, Yuning and Wang, Qimeng and Zhou, Lijuan and Liu, Xianzhi and Ma, Liwei and Wei, Jianwei},
  title = {ADAR1 Promotes the Progression and Temozolomide Resistance of Glioma Through p62‐Mediated Selective Autophagy},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2025},
  doi = {10.1111/cns.70168}
}
Kostenlos starten →